Can Lab-Made antibodies give HIV patients a break from daily pills?

NCT ID NCT06205602

NEW Ongoing Disease control Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This study tests whether two lab-made antibodies, given as a single infusion, can help control HIV in adults who are starting standard antiretroviral therapy (ART). The trial will see if these antibodies reduce the hidden virus in blood cells and delay the virus from rebounding if ART is temporarily stopped. Participants will be monitored for safety and side effects. The goal is to explore a potential path toward less frequent HIV treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Two lab-made antibodies (3BNC117-LS and 10-1074-LS) given as a one-time intravenous infusion at the start of antiretroviral therapy.
What this could lead to: If successful, this could point toward a way to keep HIV under control without daily pills, potentially allowing people to safely stop antiretroviral therapy for longer periods.
What could go wrong: This is an early-stage trial with a small number of participants. The antibodies may not work as hoped, and there is a risk of side effects or the virus becoming resistant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

CAPRISA eThekwini CRS (31422)

Durban, KwaZulu-Natal, 4011, South Africa
Durban Adult HIV CRS (11201)

Durban, 4013 SF, South Africa
Gaborone CRS (12701)

Gaborone, Botswana
University of the Witwatersrand Helen Joseph (WITS HJH) CRS (11101)

Johannesburg, Gauteng, 2193, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.